长效注射用阿立哌唑与口服阿立哌唑治疗精神分裂症患者的自主神经系统活动差异。
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia.
机构信息
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Kanagawa, Japan.
Fujisawa Hospital, 383 Kotsuka Fujisawa, Yokohama, 251-8530, Fujisawa, Japan.
出版信息
BMC Psychiatry. 2023 Mar 3;23(1):135. doi: 10.1186/s12888-023-04617-y.
BACKGROUND
Distinct oral atypical antipsychotics have different effects on autonomic nervous system (ANS) activity. Among them, oral aripiprazole has been linked to dysfunction of the ANS in schizophrenia. Long-acting injectable aripiprazole is a major treatment option for schizophrenia, but the effect of the aripiprazole formulation on ANS activity remains unclear. In this study, we compared ANS activity between oral aripiprazole and aripiprazole once-monthly (AOM) in schizophrenia.
METHODS
Of the 122 patients with schizophrenia who participated in this study, 72 received oral aripiprazole and 50 received AOM as monotherapy. We used power spectral analysis of heart rate variability to assess ANS activity.
RESULTS
Patients who received oral aripiprazole showed significantly diminished sympathetic nervous activity compared with those who received AOM. Multiple regression analysis revealed that the aripiprazole formulation significantly influenced sympathetic nervous activity.
CONCLUSION
Compared with oral aripiprazole, AOM appears to have fewer adverse effects, such as sympathetic nervous dysfunction.
背景
不同的口服非典型抗精神病药物对自主神经系统（ANS）活动有不同的影响。其中，口服阿立哌唑与精神分裂症患者的 ANS 功能障碍有关。长效注射用阿立哌唑是精神分裂症的主要治疗选择之一，但阿立哌唑制剂对 ANS 活性的影响尚不清楚。在这项研究中，我们比较了精神分裂症患者口服阿立哌唑和阿立哌唑每月 1 次（AOM）治疗对 ANS 活性的影响。
方法
本研究共纳入 122 例精神分裂症患者，其中 72 例接受口服阿立哌唑治疗，50 例接受 AOM 单药治疗。我们使用心率变异性的功率谱分析来评估 ANS 活性。
结果
与接受 AOM 治疗的患者相比，接受口服阿立哌唑治疗的患者的交感神经活性明显降低。多元回归分析显示，阿立哌唑制剂对交感神经活性有显著影响。
结论
与口服阿立哌唑相比，AOM 似乎对自主神经功能障碍等不良反应的影响较小。
Zotero 插件